177 related articles for article (PubMed ID: 21629780)
1. Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse.
Armstrong PC; Kirkby NS; Zain ZN; Emerson M; Mitchell JA; Warner TD
PLoS One; 2011; 6(5):e20062. PubMed ID: 21629780
[TBL] [Abstract][Full Text] [Related]
2. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.
Harrington LS; Lucas R; McMaster SK; Moreno L; Scadding G; Warner TD; Mitchell JA
FASEB J; 2008 Nov; 22(11):4005-10. PubMed ID: 18753249
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
Duran X; Sánchez S; Vilahur G; Badimon L
J Thromb Haemost; 2008 Aug; 6(8):1385-92. PubMed ID: 18503633
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition.
Hoxha M; Buccellati C; Capra V; Garella D; Cena C; Rolando B; Fruttero R; Carnevali S; Sala A; Rovati GE; Bertinaria M
Pharmacol Res; 2016 Jan; 103():132-43. PubMed ID: 26621246
[TBL] [Abstract][Full Text] [Related]
5. Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries.
Liu B; Luo W; Zhang Y; Li H; Zhu N; Huang D; Zhou Y
Exp Physiol; 2012 Feb; 97(2):277-89. PubMed ID: 22080487
[TBL] [Abstract][Full Text] [Related]
6. The cardiovascular pharmacology of COX-2 inhibition.
Fries S; Grosser T
Hematology Am Soc Hematol Educ Program; 2005; ():445-51. PubMed ID: 16304418
[TBL] [Abstract][Full Text] [Related]
7. A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models.
Huang SW; Kuo HL; Hsu MT; Tseng YJ; Lin SW; Kuo SC; Peng HC; Lien JC; Huang TF
Thromb Haemost; 2016 Aug; 116(2):285-99. PubMed ID: 27173725
[TBL] [Abstract][Full Text] [Related]
8. Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin.
Crescente M; Armstrong PC; Kirkby NS; Edin ML; Chan MV; Lih FB; Jiao J; Maffucci T; Allan HE; Mein CA; Gaston-Massuet C; Cottrell GS; Mitchell JA; Zeldin DC; Herschman HR; Warner TD
FASEB J; 2020 Aug; 34(8):10027-10040. PubMed ID: 32592197
[TBL] [Abstract][Full Text] [Related]
9. Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis.
Hong TT; Huang J; Barrett TD; Lucchesi BR
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H145-55. PubMed ID: 17921331
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the TP receptor in TNF-α-induced endothelial tissue factor expression.
Del Turco S; Basta G; Lazzerini G; Chancharme L; Lerond L; De Caterina R
Vascul Pharmacol; 2014 Aug; 62(2):49-56. PubMed ID: 24699252
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet effect of phloroglucinol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.
Chang MC; Chang HH; Chan CP; Chou HY; Chang BE; Yeung SY; Wang TM; Jeng JH
Toxicol Appl Pharmacol; 2012 Sep; 263(3):287-95. PubMed ID: 22789837
[TBL] [Abstract][Full Text] [Related]
12. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor.
Kearney D; Byrne A; Crean P; Cox D; Fitzgerald DJ
J Am Coll Cardiol; 2004 Feb; 43(4):526-31. PubMed ID: 14975458
[TBL] [Abstract][Full Text] [Related]
13. A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin.
Schumacher WA; Steinbacher TE; Megill JR; Durham SK
J Pharmacol Toxicol Methods; 1996 Feb; 35(1):3-10. PubMed ID: 8645878
[TBL] [Abstract][Full Text] [Related]
14. Aspirin therapy: an attempt to explain the events of prothrombotic complications after treatment discontinuation.
Doutremepuich C; Aguejouf O; Desplat V; Eizayaga FX
Thromb Haemost; 2010 Jan; 103(1):171-80. PubMed ID: 20062937
[TBL] [Abstract][Full Text] [Related]
15. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
16. Role of murine integrin alpha2beta1 in thrombus stabilization and embolization: contribution of thromboxane A2.
Kuijpers MJ; Pozgajova M; Cosemans JM; Munnix IC; Eckes B; Nieswandt B; Heemskerk JW
Thromb Haemost; 2007 Nov; 98(5):1072-80. PubMed ID: 18000613
[TBL] [Abstract][Full Text] [Related]
17. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.
Zimmermann N; Wenk A; Kim U; Kienzle P; Weber AA; Gams E; Schrör K; Hohlfeld T
Circulation; 2003 Aug; 108(5):542-7. PubMed ID: 12874188
[TBL] [Abstract][Full Text] [Related]
18. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma".
Sakata C; Kawasaki T; Kato Y; Abe M; Suzuki K; Ohmiya M; Funatsu T; Morita Y; Okada M
Thromb Res; 2013 Jul; 132(1):56-62. PubMed ID: 23522855
[TBL] [Abstract][Full Text] [Related]
19. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase 2 inhibition suppresses tubuloglomerular feedback: roles of thromboxane receptors and nitric oxide.
Araujo M; Welch WJ
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F790-4. PubMed ID: 19144694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
